Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Launches
Pharma
Roche's Vabysmo will rise above Eylea biosim threat, exec says
While Vabysmo and Ocrevus are Roche's largest assets, the biggest surprise in the company's Q3 came from Elevidys, the DMD gene therapy from Sarepta.
Angus Liu
Oct 23, 2024 11:24am
AbbVie’s Skyrizi passes Lilly’s Omvoh to take lead in colitis
Oct 7, 2024 10:53am
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
Oct 4, 2024 10:37am
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
Biogen retains biosimilars as Leqembi plows ahead
Aug 1, 2024 10:15am
Docs embrace Takeda's Eohilia, creating competition for Dupixent
Jul 22, 2024 8:57am